header logo image

LogicBio Therapeutics to Present at HC Wainwright Global Investment Conference – PR Newswire

May 20th, 2022 1:54 am

LEXINGTON, Mass., May 17, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc.(Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer,Frederic Chereau, will present a company overview at the H.C. Wainwright Global Investment Conferencebeing heldMay 23-26, 2022. The pre-recorded presentation will be available for on-demand viewing beginning at7:00 a.m. ETonTuesday, May 24, 2022.

A webcast of the presentation will be made available on the Investors section of the company's website athttps://investor.logicbio.com/. The webcast replay will be available for approximately 30 days.

AboutLogicBio Therapeutics

LogicBio Therapeuticsis a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company's gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The company's proprietary system, mAAVRx, aims to overcome some of the current limitations of AAV manufacturing by optimizing the transfection process to improve yields and product quality. The company is based inLexington, MA.For more information, visitwww.logicbio.com, which does not form a part of this release.

Investor Contacts: Stephen Jasper Gilmartin Group 858-525-2047 [emailprotected]

Media Contacts: Adam Daley Berry & Company Public Relations W:212-253-8881 C: 614-580-2048 [emailprotected]

SOURCE LogicBio Therapeutics, Inc.

Read the original post:
LogicBio Therapeutics to Present at HC Wainwright Global Investment Conference - PR Newswire

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick